Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Efficacy and safety of Hizentra® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy

Jolles, Stephen, Bernatowska, E., de Gracia, J., Borte, M., Cristea, V., Peter, H. H., Belohradsky, B. H., Wahn, V., Neufang-Hüber, J., Zenker, O. and Grimbacher, B. 2011. Efficacy and safety of Hizentra® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clinical Immunology 141 (1) , pp. 90-102. 10.1016/j.clim.2011.06.002

Full text not available from this repository.

Abstract

A prospective, open-label, multicenter, single-arm, Phase III study evaluated the efficacy and safety of Hizentra®, a 20% human IgG for subcutaneous administration, in 51 primary immunodeficiency patients over 40 weeks. Patients previously on intravenous or subcutaneous IgG were switched to weekly subcutaneous infusions of Hizentra® at doses equivalent to their previous treatment. IgG levels achieved with Hizentra® were similar to pre-study levels with subcutaneous, and higher by 17.7% than pre-study levels with intravenous IgG. No serious bacterial infections were reported in the efficacy period. The rate of all infections was 5.18/year/patient, the rates of days missed from work/school, and days spent in hospital were 8.00/year/patient and 3.48/year/patient, respectively. Local reactions (rate 0.060/infusion) were mostly mild (87.3%). No serious, Hizentra®-related adverse events were reported. Individual median infusion durations ranged between 1.14 and 1.27 h. Hizentra® maintained or improved serum IgG levels without dose increases and effectively protected patients against infections.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > R Medicine (General)
R Medicine > RM Therapeutics. Pharmacology
Uncontrolled Keywords: primary immunodeficiency, subcutaneous IgG, IgPro20, Hizentra, IgG levels, local reactions
Publisher: Springer
ISSN: 1521-6616
Last Modified: 04 Jun 2017 03:38
URI: http://orca-mwe.cf.ac.uk/id/eprint/24160

Citation Data

Cited 76 times in Google Scholar. View in Google Scholar

Cited 72 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item